Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

Promising data presented from phase II study of rifamycin SV-MMX in IBS-D

Jan. 12, 2021

Axcella provides development updates for its lead candidates

Jan. 12, 2021

Open-label study data show patients treated with LB-1148 had shorter hospital stay

Jan. 11, 2021

NorthSea reports interim phase IIb data on icosabutate in NASH

Jan. 8, 2021

Phase III induction studies of risankizumab in Crohn's disease meet primary endpoints

Jan. 8, 2021

Dosing initiates in phase IIa study of MET-409 plus empagliflozin in patients with T2DM and NASH

Jan. 8, 2021

HDGF is a therapeutic target in hepatitis

Jan. 8, 2021

Chemomab reports phase Ib data on CM-101 in patients with NAFLD

Jan. 7, 2021

Nanjing Ruijie Pharma discloses new NR1H4 agonists

Jan. 5, 2021

Promising phase II data presented for BT-11 in ulcerative colitis

Jan. 5, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...